259 related articles for article (PubMed ID: 2871585)
21. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.
Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN
Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of complement components in polyethylene glycol precipitated immune complexes from patients with ovarian cancer and patients with rheumatoid arthritis.
Mooney NA; Hay FC; Poulton TA
Clin Exp Immunol; 1983 Jun; 52(3):561-8. PubMed ID: 6603297
[TBL] [Abstract][Full Text] [Related]
23. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
[TBL] [Abstract][Full Text] [Related]
24. The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. II. Effects on immune and inflammatory indices in peripheral blood.
Smith MD; Ahern MJ; Brooks PM; Roberts-Thomson PJ
J Rheumatol; 1988 Feb; 15(2):233-7. PubMed ID: 3361535
[TBL] [Abstract][Full Text] [Related]
25. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
Cambridge G; Leandro MJ; Edwards JC; Ehrenstein MR; Salden M; Bodman-Smith M; Webster AD
Arthritis Rheum; 2003 Aug; 48(8):2146-54. PubMed ID: 12905467
[TBL] [Abstract][Full Text] [Related]
26. Complement activation, circulating C1q binding substances and inflammatory activity in rheumatoid arthritis: relations and changes on suppression of inflammation.
Berglund K; Laurell AB; Nived O; Sjoholm AG; Sturfelt G
J Clin Lab Immunol; 1980 Jul; 4(1):7-14. PubMed ID: 7463476
[TBL] [Abstract][Full Text] [Related]
27. [Long term treatment of rheumatoid arthritis. Experiences with D-penicillamine in comparison with gold and immunosuppressive drugs (author's transl)].
Warnatz H; Scheiffarth F; Gutmann W
Med Klin; 1975 Sep; 70(38):1509-15. PubMed ID: 810648
[TBL] [Abstract][Full Text] [Related]
28. Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: correlation with erythrocyte sedimentation rate or C-reactive protein.
Cohick CB; Furst DE; Quagliata S; Corcoran KA; Steere KJ; Yager JG; Lindsley HB
J Lab Clin Med; 1994 May; 123(5):721-7. PubMed ID: 8195678
[TBL] [Abstract][Full Text] [Related]
29. 125I-C1q binding activity of soluble antigen-antibody complexes formed in vitro.
Soltis RD; Hasz DE
J Clin Lab Immunol; 1982 Nov; 9(2):121-31. PubMed ID: 6984078
[TBL] [Abstract][Full Text] [Related]
30. Detection and partial characterization of immune complexes in patients with rheumatoid arthritis plus Sjogren's syndrome and with Sjogren's syndrome alone.
Yoshinoya S; McDuffy S; Alarcon-Segovia D; Pope RM
Clin Exp Immunol; 1982 May; 48(2):339-47. PubMed ID: 6980743
[TBL] [Abstract][Full Text] [Related]
31. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
32. [Effect of clinical activity and D-penicillamine or gold treatment on the occurrence of serum immune complexes in patients with rheumatoid arthritis].
Brühl W; Swierczyńska Z; Cygler B; Woźniczko-Orłowska G
Reumatologia; 1979; 17(3):303-6. PubMed ID: 515575
[No Abstract] [Full Text] [Related]
33. [Topical use of Rheumon-Gel in the combined treatment of patients with rheumatoid arthritis].
Cherevatov BG; Shelest AN; Volnenko NB; Cherevatova SKh
Ter Arkh; 1987; 59(12):100-2. PubMed ID: 3447280
[TBL] [Abstract][Full Text] [Related]
34. Circulating immune complexes in rheumatoid arthritis: a prospective study using five immunoassays.
Reynolds WJ; Yoon SJ; Emin M; Chapman KR; Klein MH
J Rheumatol; 1986 Aug; 13(4):700-6. PubMed ID: 3490573
[TBL] [Abstract][Full Text] [Related]
35. Sulphasalazine in the treatment of rheumatoid arthritis.
Pelísková Z; Vácha J; Trnavský K
Z Rheumatol; 1985; 44(6):263-6. PubMed ID: 2869625
[TBL] [Abstract][Full Text] [Related]
36. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
[TBL] [Abstract][Full Text] [Related]
37. Virus-induced immune complex disease: genetic control of C1q binding complexes in the circulation of mice persistently infected with lymphocytic choriomeningitis virus.
Oldstone MB; Tishon A; Buchmeier MJ
J Immunol; 1983 Feb; 130(2):912-8. PubMed ID: 6217255
[TBL] [Abstract][Full Text] [Related]
38. Elevated serum beta 2-microglobulin levels and C1q-binding immune complexes in sarcoidosis.
Mornex JF; Revillard JP; Vincent C; Deteix P; Brune J
Biomedicine; 1979 Nov; 31(7):210-3. PubMed ID: 93496
[TBL] [Abstract][Full Text] [Related]
39. Circulating immune complexes in patients with cryptogenic fibrosing alveolitis.
Haslam PL; Thompson B; Mohammed I; Townsend PJ; Hodson ME; Holborow EJ; Turner-Warwick M
Clin Exp Immunol; 1979 Sep; 37(3):381-90. PubMed ID: 315841
[TBL] [Abstract][Full Text] [Related]
40. Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period.
Capell HA; Marabani M; Madhok R; Torley H; Hunter JA
Q J Med; 1990 Apr; 75(276):335-44. PubMed ID: 1974723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
